PPIAP74: A Potential Drug Target and Biomarker (G131055)

Target Name: PPIAP74

NCBI ID: G131055

PPIAP74

Other Name(s): LOC131055 | peptidylprolyl isomerase A pseudogene 74 | Peptidylprolyl isomerase A (cyclophilin A) pseudogene

PPIAP74: A Potential Drug Target and Biomarker

PPIAP74, also known as LOC131055, is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. Its function and specificity are not yet fully understood, but research has shown that it plays a critical role in several biological processes. As a drug target and biomarker, PPIAP74 has great potential in the development of new treatments for various diseases.

The Protein PPIAP74

PPIAP74 is a member of the superfamily of cytoplasmic proteins, which are involved in various cellular processes, including cytoskeletal organization, intracellular signaling, and inflammation. It consists of 255 amino acid residues and has a calculated molecular mass of 31 kDa. PPIAP74 is expressed in a variety of tissues, including the brain, heart, and kidneys, and has been shown to localize to the endoplasmic reticulum (ER) and the nuclear envelope (NE).

Function and Specificity

The function of PPIAP74 is not yet fully understood, but research has shown that it plays a critical role in several biological processes. One of its key functions is in the regulation of mitochondrial function and energy metabolism. Studies have shown that PPIAP74 is a component of the mitochondrial protein complex VDAC, which is responsible for importing and translating mitochondrial proteins into the mitochondria. Additionally, PPIAP74 has been shown to play a role in the regulation of cellular signaling pathways, including the TGF-β pathway, which is involved in cell growth, differentiation, and survival.

Drug Target Potential

PPIAP74 has great potential as a drug target due to its unique function and its expression in various tissues. Its localization to the ER and NE suggests that it may be involved in the delivery and processing of proteins to the cell surface. As a result, PPIAP74 may be a good candidate for drugs that target the ER and NE, such as those used to treat neurodegenerative diseases. Additionally, its role in the regulation of mitochondrial function and energy metabolism suggests that it may be involved in the treatment of diseases related to mitochondrial dysfunction, such as those used to treat cardiovascular disease.

Biomarker Potential

PPIAP74 has the potential to serve as a biomarker for several diseases. Its expression has been shown in a variety of tissues, including the brain, heart, and kidneys, making it a potential biomarker for these diseases. Additionally, its role in the regulation of mitochondrial function and energy metabolism suggests that it may be involved in the development and progression of certain diseases, such as those related to aging or neurodegenerative diseases.

Conclusion

PPIAP74 is a protein that has great potential as a drug target and biomarker. Its unique function and its expression in various tissues make it a promising candidate for new treatments for a variety of diseases. Further research is needed to fully understand its role in biology and to develop new treatments based on its properties.

Protein Name: Peptidylprolyl Isomerase A Pseudogene 74

The "PPIAP74 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PPIAP74 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets